43 research outputs found

    Additional file 1 of Effects of Enteromorpha prolifera polysaccharides on growth performance, intestinal barrier function and cecal microbiota in yellow-feathered broilers under heat stress

    No full text
    Additional file 1: Table S1. The chemical and monosaccharide composition of seaweed-derived polysaccharides (SDP) from Enteromorpha prolifera. Table S2. The formulation and nutrient level of the basal diets. Table S3. Primer information of real-time quantitative PCR

    Vitamin E Succinate-Grafted-Chitosan Oligosaccharide/RGD-Conjugated TPGS Mixed Micelles Loaded with Paclitaxel for U87MG Tumor Therapy

    No full text
    The poor therapeutic efficacy of hydrophobic chemotherapeutic drugs is an intrinsic limitation to successful chemotherapy. In the present study, a multitask delivery system based on arginine-glycine-aspartic acid peptide (RGD) decorated vitamin E succinate (VES)-grafted-chitosan oligosaccharide (CSO)/RGD-conjugated d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS-RGD) mixed micelles (VeC/T-RGD MM) was first prepared for targeted delivery of a hydrophobic anticancer drug, paclitaxel (PTX), to improve the efficacy of U87MG tumor therapy. VES grafted CSO (VES-<i>g</i>-CSO) and TPGS-RGD were synthesized as nanocarriers, and PTX loaded VeC/T-RGD MM (PTX@VeC/T-RGD MM) was prepared via the organic solvent emulsification–evaporation method. The PTX@VeC/T-RGD MM was 150.2 nm in diameter with uniform size distribution, 5.92% drug loading coefficient, and no obvious particle size changes within 7 days. The PTX@VeC/T-RGD MM showed sustained-release properties <i>in vitro</i> and high cytotoxicity, and could be efficiently taken up by human glioma U87MG cells. The tumor inhibitory rate of PTX@VeC/T-RGD MM treatment in U87MG tumor spheroids and U87MG tumor bearing mice was 49.3% and 88.4%, respectively, which indicated a superior therapeutic effect. PTX@VeC/T-RGD MM did not damage normal tissues in safety evaluations. These findings suggested that PTX@VeC/T-RGD MM could be developed for the delivery of hydrophobic drugs to U87MG tumors

    CSO-g-CM-β-CD synthesis and characterization.

    No full text
    <p>Synthetic route of CSO-g-CM-β-CD (A); FT-IR spectra of CSO-g-CM-β-CD and CSO (B) and <sup>1</sup>H-NMR spectra of CSO and CSO-g-CM-β-CD in D<sub>2</sub>O (C).</p

    Fluorescence analysis.

    No full text
    <p>Fluorescence scanning analysis with pyrene (A) and critical micelle concentration of CSO-g-CM-β-CD@AD-PTX solution (B).</p

    AD-PTX synthesis and characterization.

    No full text
    <p>Synthetic route of AD-PTX (A); LC-MS spectra of AD-PTX (B) and <sup>1</sup>H-NMR spectra of AD, PTX and AD-PTX in DMSO-d<sub>6</sub> (C).</p

    Effect of MG132 on VEGF and p53 expression induced by active Rac1/Cdc42.

    No full text
    <p>(A) GST–MCF-7, V12Rac1–MCF-7, and L61Cdc42–MCF-7 cells were incubated, and MG132 was added to select samples for 12 and 24 h, respectively. After incubation, the media were analyzed for VEGF levels using ELISA assay; cell numbers were counted. Data are expressed as the mean ± standard deviation (SD) for three independent experiments. Statistical significance was assessed with one-way ANOVA and Student's t-test. *<i>P</i><0.05, **<i>P</i><0.01, for the GST–MCF-7 group vs V12Rac1– or L61Cdc42–MCF-7 group. #<i>P</i><0.05, ##<i>P</i><0.01, for the MG132-added group vs the no-MG132-added group. (B, C) MCF-7, GST–MCF-7, V12Rac1–MCF-7 and L61Cdc42–MCF-7 cells were incubated, and MG132 was added to select samples for 24 h. After incubation, the cells were analyzed by western blot assay. p53, p21 and β-actin expression was examined. β-actin protein levels were used as a loading control. (D) The immunoprecipitation assay was performed as described in Material and Methods. Total protein was extracted from MCF-7, GST–MCF-7, V12Rac1–MCF-7 and L61Cdc42–MCF-7 cells and subjected to an immunoprecipitation assay. p53 protein expression was examined. β-actin protein levels were used as a loading control.</p
    corecore